Cellular therapy has become one of the most effective methods for treating cancer over the last decade, yet it remains largely inaccessible. CAR-T therapy is manufactured from a patient's own cells, which requires a separate production cycle for each individual and involves high costs and long waiting times, making it unavailable to most patients.
An alternative approach is the pre-manufacture of therapy using healthy donor cells, allowing it to be used 'off the shelf' as needed by the patient. This is what allogeneic cell therapy entails, which is the focus of East Ocyon Bio.
The Private Limited company was founded in Gurugram in 2022 by Dinesh Kundu, who serves as the Chief Executive Officer and holds MBBS and MBA degrees, alongside Renu Kundu and Narinder Mehra.
The company's stated goal is to develop therapies within India and bring them to global markets simultaneously, rather than years after their launch in the West. East Ocyon Bio aims to bridge this gap, as drugs approved in Europe and the United States historically reach Indian patients significantly later than their release.
The company declares its intention to create indigenous treatments for cancer, autoimmune diseases, and rare illnesses that possess therapeutic potential.
The company's platform utilizes Natural Killer (NK) cells, which are part of the body's first line of immune defense. These cells are sourced from healthy donors and modified to carry a Chimeric Antigen Receptor (CAR), which directs them toward a specific target. This approach is known as CAR-NK therapy.
The company asserts that synthetic biology and non-viral cell engineering are employed to produce these cells, ensuring an allogeneic and ready-to-use product. In addition to CAR-NK, the company's website lists developments in CAR-gamma-delta T-cell therapy, CRISPR gene editing, and mRNA.
Although CAR-NK is not an invention of East Ocyon Bio, it is a rapidly evolving global field of research. The board of technology describes CAR-NK as a potentially safer and more scalable alternative to CAR-T because it carries a lower risk of severe immune reactions that CAR-T can induce. The company's proposal is to establish an Indian platform for this technology.
Currently, none of these methods have been tested on patients. The seed funding round is intended to finance preclinical trials, the construction of a facility compliant with Good Manufacturing Practice (GMP) standards, and reaching Phase I clinical trials, although the company has not yet announced the start of this stage.
In February 2026, the Technology Advisory Board at the Ministry of Science and Technology provided the company with financial assistance for a project titled 'Development of CAR-NK based cellular therapy and clinical trials for intractable tumors and leishmaniasis.' The grant amount was not disclosed.
As part of this project, the company proposed developing anti-PD-L1 CAR-NK therapy for resistant solid tumors concurrently with work on leishmaniasis. The board described the objective as creating India's first ecosystem platform for off-the-shelf CAR-NK therapies, intended to reduce dependence on expensive imported treatments.
The seed round was closed in December 2024, raising $4.2 million through the joint participation of Aeravti Ventures and Micro Labs, a Bengaluru-based pharmaceutical company. Rishab Singh from Aeravti Ventures noted at the time that there is a significant unmet medical need and a lag in access to innovative treatments in India.
According to the company's database figures, revenue for the year ending March 2024 was approximately 2.33 lakh rupees, with a staff size of 14 people. Beyond the grant announcement, no public statements have been made regarding clinical results, trial registrations, manufacturing sites, or partnerships.
On August 3rd of this year, American writer George R.R. Martin published a text on his personal blog titled 'Better late than never.' This was his first publication in about six months, presenting a tone of outpouring.
Martin shared that the year has been extremely stressful, filled with overwhelming events, both positive and negative, including the loss of friends. He admitted to struggling with sadness and depression, and commented that, having turned seventy-seven last September, he feels that growing old no longer holds charm.
Recently, George has dedicated his time to several projects, such as the adaptations of The Knight of the Seven Kingdoms and House of the Dragon for HBO, in addition to the game Elden Ring, based on a game he helped create. He is also continuing to edit the new volumes of Wild Cards, a science fiction anthology released almost annually.
The biggest interest of followers lies in The Winds of Winter, the sixth volume of the A Song of Ice and Fire saga. Martin took fifteen years to publish the initial five books, and separated the last volume, A Dance with Dragons (2011), from the current year. Due to this slowness, many fans have voiced public complaints, pressuring for the completion of the book.
In January of this year, the author informed the Hollywood Reporter that The Winds of Winter already has 1,100 pages written, but without a scheduled release date. There are speculations that the author's depression may be linked to the criticism he receives online, given that in 2025 he made a post mocking the hatred of internet users.
In that post, Martin declared: 'Some of you will get angry about this, just like you get angry about everything I announce here that is not about Westeros or THE WINDS OF WINTER. You gave up on me, or on the book. I will never finish THE WINDS OF WINTER. If I finish it, I will never finish A SPRING DREAM. If I finish it, it won't be good. I should hire another writer to replace me... Anyway, I will die soon because I am too old. I lost all interest in A Song of Ice and Fire decades ago. I don't care about writing anymore, I just sit around wasting my money.'
Although it is uncertain if these issues are interconnected, there are other notable writers who have publicly faced mental health problems.
Patches intended for pimple treatment have gained great popularity in both pharmacies and social media, presenting various variations in colors and shapes. However, the question arises whether these items truly help combat acne.
The effectiveness of these products is directly linked to the type of lesion. The most common patches, made with hydrocolloid, have the ability to accelerate healing and reduce inflammatory signs of certain pimples, although they cannot replace complete dermatological treatment nor work in all situations.
According to dermatologist Glauce Eiko from the Brazilian Society of Dermatology (SBD), these patches work by absorbing the secretion of the pimple and maintaining a moist and controlled environment, which is ideal for healing. They act as a physical barrier, preventing the lesion from coming into contact with friction, manipulation, or contamination, which could result in secondary infections and scarring.
The indication and success level of the patch change according to the stage of the pimple's development. The best performance is observed when the lesion already has a pustule with a white head. In this scenario, hydrocolloid is highly effective at actively sucking out pus and exudate, resulting in reduced swelling, volume, and redness.
Patches are also recommended when the pimple has already ruptured, functioning as a dressing that protects the area from dirt and ultraviolet radiation, preserving the skin's natural moisture and promoting healing.
In early stages of inflammation, characterized only by a sensitive papule without a white head, the benefit is smaller, restricted mainly to the function of a barrier against manipulating the lesion. For internal pimples, such as deep nodules and cysts, as well as for comedones (open or closed blackheads), patches offer no advantages.
There are also patches that incorporate active substances such as salicylic acid, niacinamide, and microneedles; the latter being small soluble structures that release components directly into the lesion. However, dermatologist Barbara Miguel from Einstein Israelite Hospital points out that scientific evidence regarding the extra benefit of these substances is still limited.
To ensure safety, it is essential to purchase only products registered by the National Health Surveillance Agency (Anvisa). Good application practices include ensuring that the skin is clean and completely dry, avoiding the application of creams, serums, or oils on the pimple, as these decrease the material's adhesion.
The patch must cover the lesion entirely and be gently pressed for ten to twenty seconds to ensure proper fixation. The ideal duration of wear is between six and twenty-four hours, or until the hydrocolloid becomes opaque and whitish, indicating maximum secretion absorption.
Users of retinoids or benzoyl peroxide should be cautious when applying these products under the patch. If they are part of the routine, acids should only be applied to the areas adjacent to the lesion, as the occlusion generated by the patch can intensify the penetration of substances and cause severe irritation. When removing the patch, the guidance is to do so slowly along the edges and lightly moisturize the area to aid in restoring the skin barrier.
Barbara Miguel emphasizes that none of these procedures replaces the advice of a dermatologist, warning that such products do not treat the origin of acne. People with moderate to severe or recurrent acne need specialized evaluation to treat the inflammatory process and prevent scars.
Singapore is employing an unusual strategy to combat dengue fever by releasing ten million mosquitoes every week. These insects are not ordinary; they are specially bred male mosquitoes of the Aedes genus carrying the naturally occurring Wolbachia bacterium.
When these males mate with wild females, their eggs do not hatch, which helps reduce the mosquito population. This approach aims not just to eliminate insects but to use biological methods to disrupt their reproduction and decrease disease transmission.
This strategy is already showing promising results. In some areas of Singapore, the Aedes mosquito population has decreased by 90%, and a recent trial showed about 71% protection against dengue infection.
In the context of the situation in India, where 2.33 lakh cases of dengue were registered in 2024, the question arises about the possibility of applying this unconventional tactic to solve the dengue problem in India.
